ReviewEcancermedicalscience2020
Cervical cancer: a meta-analysis, therapy and future of nanomedicine.
Review in Ecancermedicalscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-Genetic Factors and Risk of Cervical Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.International journal of public health · 2023Pooled it
- Global trends and insights in cervical cancer research: a bibliometric analysis from 2000 to 2024.Reproduction & fertility · 2026Article
- Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies.Molecular medicine (Cambridge, Mass.) · 2026Review
- Functionalized Core/Shell Gold-Palladium Bimetallic Nanoparticles in Transferrin-Targeted Dual-Drug Delivery in a Cervical Cancer Cell Model.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Hsa_circ_0101308 adjusted by N6-methyladenosine (mCancer biomarkers : section A of Disease markers · 2025Article
- Nanotheranostics for gynecological cancers: a path forward for Africa.Medical oncology (Northwood, London, England) · 2024Review
- Exploring the Intricacies of Cervical Intraepithelial Neoplasia and Its Connection with HPV: A Narrative Review.Iranian journal of public health · 2024Review
- Cervical cancer: Challenges and prevention strategies: A narrative review.Health science reports · 2024Review
- Copolymer-Green-Synthesized Copper Oxide Nanoparticles Enhance Folate-Targeting in Cervical Cancer Cells In Vitro.Polymers · 2023Article
- Genotyping and Phylogenetic Analysis of Human Papillomaviruses in Formalin Fixed Paraffin Embedded Sections from Cervical Lesions in Duhok-Iraq.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Effects of Fractionated Radiation Exposure on Vimentin Expression in Cervical Cancers: Analysis of Association with Cancer Stem Cell Response and Short-Term Prognosis.International journal of molecular sciences · 2023Article
- OTX1 promotes tumorigenesis and progression of cervical cancer by regulating the Wnt signaling pathway.Oncology reports · 2022Article
- The Potential of Curcumin-Capped Nanoparticle Synthesis in Cancer Therapy: A Green Synthesis Approach.Nanomaterials (Basel, Switzerland) · 2022Review
- Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells.Drug delivery · 2021Article
- Green Metallic Nanoparticles for Cancer Therapy: Evaluation Models and Cancer Applications.Pharmaceutics · 2021Review
- Worldwide initiatives to eliminate cervical cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021Article
- The Involvement of Natural Polyphenols in the Chemoprevention of Cervical Cancer.International journal of molecular sciences · 2021Review
- Investigation of the association between ten pathogens causing sexually transmitted diseases and high-risk human papilloma virus infection in Shanghai.Molecular and clinical oncology · 2021Article
- Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.Oncology letters · 2021Article
- A Novel Biological Activity of the STAT3 Inhibitor Stattic in Inhibiting Glutathione Reductase and Suppressing the Tumorigenicity of Human Cervical Cancer Cells via a ROS-Dependent Pathway.OncoTargets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is one of the leading causes of female death, with an annual mortality rate exceeding 200,000 in developing communities. Despite the past decade bearing witness to a reduction in cervical cancer cases throughout developed countries, the prevalence in developing countries continues to rapidly rise. The increase in cervical cancer cases is attributed to the lack of financial resources and the unavoidable risk factors of the disease. Traditional means of anticancer therapy are compromised by reduced drug potency, non-specificity, negative side effects and the development of multiple drug resistance (MDR), which leads to a decrease in the long-term anticancer therapeutic efficacy. Recent advances in nanomedicine have elucidated the potential of nanoparticles to reduce the side effects and improve the survival rate of patients, by enhancing selective delivery and uptake of photosensitive, therapeutic and genetic material to cervical cancer cells, thereby enhancing antitumour efficiency. This review paper analyses the risk factors and epidemiology of cervical cancer globally, especially in developing communities, whilst demonstrating the enhanced anticancer treatment using selected nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.